RoslinCT, a Hopkinton-based biotechnology company, was recognized recently as a Manufacturer of the Year by the Commonwealth of Massachusetts at the ninth annual Manufacturing Awards.

State Rep. James Arena-DeRosa, whose district includes Hopkinton, nominated the company for this award, his office announced in a press release. The release cited RoslinCT’s cutting-edge cell and gene therapy as well as its leadership in the biotechnology industry.

“I was delighted to nominate RoslinCT for the Massachusetts Manufacturing Awards this year,” stated Arena-DeRosa. “This amazing event highlights manufacturers from across the commonwealth who are national leaders in fields such as green energy, biotechnology and even breweries. It was an honor to bring a company whose innovative gene cell therapies are changing the landscape of healthcare treatment.”

He added that he was first introduced to RoslinCT via a tour of the Hopkinton facility on South Street with Gov. Maura Healey and Lt. Gov. Kim Driscoll.

“Our MetroWest region has the potential to lead the commonwealth in the next wave of biomanufacturing,” Arena-DeRosa continued, “and this company exemplifies the advanced technology manufacturing being conducted every day here in the district and across the state.”

Each year, the Massachusetts Legislative Manufacturing Caucus hosts the ceremony to highlight many of the commonwealth’s most noteworthy manufacturers and celebrate their successes as leading manufacturers in their respective industries. This year, more than 50 diverse manufacturers were selected by legislators from across the state to be recognized at the Sept. 25 event at Gillette Stadium.

The company, which has manufacturing suites in Hopkinton and Scotland, has produced groundbreaking gene therapy treatments for blood diseases including sickle cell disease and transfusion-dependent beta thalassemia.

“We are extremely proud to receive this recognition from the Commonwealth of Massachusetts,” stated Garry Menzel, president of RoslinCT, in a company press release. “Our team is dedicated to advancing the development of transformative cell and gene therapies through excellence in manufacturing and innovation. This award reflects the incredible work our teams are doing to push the boundaries of what’s possible in this field.”

“This honor showcases the strength of our Hopkinton facility and the strategic investments we’ve made to deliver high-quality cell therapy products,” added Dean Morris, RoslinCT U.S.’s chief operating officer. “As we continue to expand and automate our operations, we are committed to driving efficiency and supporting the needs of our clients and their patients.”

SUBHED: Lafleur joins Northeast Dermatology

Northeast Dermatology Associates recently announced the newest addition to its team, Audra Lafleur, FNP-BC. With more than two decades of experience in dermatology, she provides services including acne treatment, dermal fillers, neurotoxins, psoriasis treatment, skin cancer screening and chemical peels.

“We are thrilled to have Audra Lafleur join our team at Northeast Dermatology Associates. Her extensive background in dermatology, aesthetics and patient care truly sets her apart, and we are confident that she will provide exceptional care to our patients,” said Evan Smith, regional vice president of operations.